Lower initial exposure may reduce early side effects, and improved tolerability can make it easier for patients to remain on therapy long enough to evaluate its benefits
The research community studying dual agonism has documented mean body weight reductions in the 20-22% range a roughly 35-50% improvement over the single-receptor benchmark
If theres a significant imbalance of bacteria in your gut, it may take longer to see a noticeable effect
The anti-fibrotic properties extend beyond single organs
PLoS ONE 11(12):e0165589 Nichols AR, Aris I, Rifas-Shiman SL, Hivert MF, Chavarro JE, Oken E (2025) History of pregnancy loss and risk for higher midlife blood pressure in parous females
Once through the adjustment period, most users find sustainable, genuine energy improvements that stimulant-based drugs cannot provide